I love starting the weekend with sunrise on top of Mount Washington!
Art Krieg
@artkrieg.bsky.social
Love trail running, hiking, Toll-Like receptors 7/8/9, P1 pDC. Founder/CEO of Zola Therapeutics
TLR7/8 don't "just" detect viral RNA: they also have an antagonist site to prevent activation by self RNA! Understanding and controlling this system is key to immunotherapy for cancer and autoimmunity. Definitely one of the coolest papers I've read in a long while.
How does your immune system tell pathogenic RNA from your own, even though they’re made of the same stuff? Our latest paper with @gantierlab.bsky.social shows some self RNA act as an off switch preventing autoimmunity in the absence of pathogens. 🧬🔬⭐ www.nature.com/articles/s41590-026-02429-2
Every now and then I read a paper that opens my eyes to see an aspect of biology in a new way. This paper blew my mind - TLR7/8 have agonist sites to bind viral RNA, and antagonist sites to bind endogenous RNA degrad. products, enabling self/nonself discrimination: www.nature.com/articles/s41...
nature.com
As a someone with a 33 year NIH-funded lab whose grant is supposed to be reviewed this week, shut NIH down if that is what's needed to end ICE terrorism. Innocent lives are more important 🧪
The Senate may choose to vote together on the DHS and LHHS bills. Thus, a filibuster on DHS may mean no funding for NIH. What my colleagues are saying: “Shut it down, public health will understand. I’ll work without pay again.” - anonymous NIHer
Point blank. 10-shots. Execution. A US citizen, a VA ICU Nurse. Then lying. Blocking a real investigation.
Why can't corporate media use this straight-up language? It's not complicated.
Federal Agents Kill Again; Gunmen Still At Large | Defector
On Saturday in Minneapolis, federal agents surrounded 37-year-old Veterans Affairs intensive care nurse Alex Jeffrey Pretti, who’d been filming them in the street with his phone camera as they conduct...
defector.com
The story is not that there are two conflicting versions of what happened. The story is that the federal government is lying about what happened. There is plenty of evidence. Your job, our job, is to sift that evidence and describe what actually happened ffs.
May we all be Alex. Our government murdered him, lied about it, and are trying to obstruct justice. We the people demand justice.
A video of Alex Pretti reading out the final salute of an unnamed veteran he cared for until the end of his life in the ICU, posted to Facebook by his son.
Just got my poster set up at #SITC2025 and walking my first visitor through our data. If you’re here, stop by poster 919 to learn about the unique biology of TLR7/8/9!
Delighted that Luke Timmerman invited me on his Long Run podcast to tell Zola's story. It's been a long run for me, from discovering CpG DNA (TLR9) 30 yrs ago, to now discovering RNA/DNA TLR7/8/9 agonists, which may transform cancer immunotherapy! timmermanreport.com/2025/10/inna...
Innate Immune System Activators for Cancer: Art Krieg on The Long Run - TimmermanReport.com
Art Krieg is today’s guest on The Long Run. Art is the founder and CEO of a Cambridge, Mass.-based startup called Zola Therapeutics. Zola is developing an oligonucleotide drug candidate to activate a ...
timmermanreport.com
Join us for the 3rd Nature Conference on Nucleic Acid Medicines in Boston (Dec 8-10) with an amazing lineup of speakers. 4 weeks left 4 early bird registration! natureconferences.streamgo.live/cracking-the... @natureportfolio.nature.com @nature.com @natbiotech.nature.com @natrevdrugdiscov.nature.com
My new review article covers key points I have not seen in any other review of cancer immunotherapy: i) the difference between IFN-a and IFN-b; ii) the unique role of P1 pDC among all DC subsets; iii) the unique role of TLR7/8/9 among TLRs nam10.safelinks.protection.outlook.com?url=http%3A%...
New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity
The role of type I interferon (IFN) in mediating tumor immunosurveillance, in situ vaccination, and response to other cancer immunotherapies is well established. The biologic and species-specific diff...
nam10.safelinks.protection.outlook.com
If you are an academic innovator interested in learning more about translating your research to real-world impact, apply to be a Termeer Scholar! Get your application in by Friday, August 29th at Midnight EST to be considered for this incredible opportunity! www.linkedin.com/posts/termee...
#termeerscholars #academicinnovation #lifesciences #biotech #healthcareimpact #techtransfer #commercialization #patientdrivenscience #benchtobedside #labtopatientjourney | Termeer Institute
Only 3 days remain to apply for the Termeer Scholars Program! Why Apply? Join a two-day workshop designed to support your journey from the bench to bedside. You'll gain practical skills, industry ins...
linkedin.com
I recently had the pleasure of joining The Pharmaverse podcast - it released today. We discussed the parallels between running marathons (and ultras) and my >30 yrs of efforts activating immunity to fight cancer, culminating in founding Zola Rx, starting a biotech is harder! youtu.be/FX9MLqv9PBQ
Season 2, Episode 13: Finding A Path Forward with Art Krieg
YouTube video by The Pharmaverse Podcast
youtu.be
Like most immunologists, I tend to use a lot of jargon when talking about cancer immunotherapy - so complex! A patient in one of our prior clinical trials asked me to explain our new approach with TLR7/8/9 agonists, and I made this video on the history, which he liked. youtu.be/KLgCU5Gm3pA
A brief history of cancer immunotherapy, for non-immunologists and patients
YouTube video by Art Krieg
youtu.be
Thank you Brad Loncar for hosting us on Biotech TV - Jim and I appreciated the chance to explain how a deeper understanding of type one IFNs can propel cancer immunotherapy forward to greater success! RNA/DNA hybrids costimulate TLR7/8/9, inducing a novel IFN-a response without inflammation!
𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Biotech veteran @artkrieg.bsky.social explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP. Full video: www.biotechtv.com/post/zola-th...
Can Cambridge biotech evolve with the times? I’m an optimist, but the challenges we face are clear and growing…
Can Kendall Square retain its dominant position? medium.com/@isaacstoner...
Tickets are SOLD OUT for the TR10 East Coast anniversary party Mar. 6 in Cambridge, Mass. Tickets still available for TR10 West Coast party Mar. 13. Register here. www.eventbrite.com/e/tr10-west-...
TR10 West Coast Party
TR10 West Coast Party. Join a stellar cast of biotech leaders at the TR10 West Coast Party for toasts and roasts of founder Luke Timmerman.
eventbrite.com
Cold day going up Mount Washington today with Doug Fambrough, Dave Melville, Jim Ellis, and friends! On the way up, Doug agreed to join me on the board of my new company, Zola therapeutics, getting work done while having fun!
A drug comprising 8 defined live bacterial strains reduces C diff. by >80%, cool!
Today our team published additional results from the Phase 2 CONSORTIUM study for our lead candidate, VE303, a potential first-in-class Live Biotherapeutic Product which is being evaluated for prevention of recurrent Clostridioides difficile infection (rCDI). full-text access: rdcu.be/d5ovX
I joined 75+ @nobelprize.bsky.social laureates urging US Senators to oppose RFK Jr.'s confirmation as DHHS Secretary. If you’re in a state with GOP senators, PLEASE reach out to them! I’d deeply appreciate it if you amplified this post! 🙏 www.nytimes.com/2024/12/09/h...
Mount Lafayette and Franconia Ridge are completely different in the winter, my favorite time of year to be up here!#AnotherGreatDayInTheMountains
It’s another great day to be in the mountains! Heading up the Old Bridle Path in Franconia notch…
It’s full on winter on Mount Washington, but the Lake of the Clouds hut still provides a nice wind break for hot coffee and a snack. Excellent conditions snowshoeing up ammo. Just past the hut, the trail disappears under deep drifts and there’s no visibility with blowing snow. Back down ammo!
Sunset right now in the blue Hills, the rocks are still a bit wet from the recent rain, so I’m taking it easy, enjoying the views!
For my inaugural post, I’m sharing this recent talk on the immune considerations in mRNA therapeutics. Optimizing CD8+ T cell responses requires understanding the biology of IFN-a/b, which has been ignored in recent cancer immunotherapy review articles. youtu.be/Isz5FqRpqbM
mRNA Therapeutics: immunological issues (from 9th Int. Vaccines R&D Conference, Boston, Nov. 2024)
YouTube video by Art Krieg
youtu.be